OptiBiotix Health PLC
LSE:OPTI
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| UK |
|
OptiBiotix Health PLC
LSE:OPTI
|
6.5m GBP |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
398.4B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.2B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
180.2B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
38.3B EUR |
Loading...
|
Market Distribution
| Min | -1 510% |
| 30th Percentile | 0.4% |
| Median | 0.5% |
| 70th Percentile | 0.7% |
| Max | 7 323.1% |
Other Profitability Ratios
OptiBiotix Health PLC
Glance View
Optibiotix Health Plc is engaged in the research and development of compounds that modify the human microbiome. is a life sciences company. The firm is primarily engaged in identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry segment. The Company’s technology platforms include OptiBiome, OptiScreen and OptiBiotic. Its OptiBiome technology platform that screens identifies and/or develops microbiome modulators, which can be used in formulations to prevent, manage and a range of chronic lifestyle diseases. The Company’s OptiScreen pharmaceutical screening platform to identify microbial metabolic pathways that interact with human pathways to improve health. Its OptiBiotic platform generates oligosaccharides and screens them for their ability to modulate specific microbial genera or species and their microbial end products (short chain fatty acids, such as acetate, propionate, butyrate) and physical properties (sweetness). Its products include SlimBiome, SweetBiotix, CholBiome, SlimBiome Medical and WellBiome.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for OptiBiotix Health PLC is 45.4%, which is below its 3-year median of 46.1%.
Over the last 3 years, OptiBiotix Health PLC’s Gross Margin has decreased from 56.8% to 45.4%. During this period, it reached a low of 38% on Dec 31, 2024 and a high of 56.8% on Jun 30, 2022.
